Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities (2016 - 2025)

Viking Therapeutics' Cash from Financing Activities history spans 12 years, with the latest figure at $75.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 7410.3% year-over-year to $75.1 million; the TTM value through Dec 2025 reached $76.4 million, down 87.52%, while the annual FY2025 figure was $76.4 million, 87.52% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $75.1 million at Viking Therapeutics, up from $480000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $606.0 million in Q1 2024 and bottomed at -$5.0 million in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $753500.0 (2024), against an average of $48.6 million.
  • The largest annual shift saw Cash from Financing Activities soared 22770.21% in 2022 before it crashed 840.0% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $47000.0 in 2021, then skyrocketed by 22770.21% to $10.7 million in 2022, then plummeted by 98.25% to $188000.0 in 2023, then skyrocketed by 431.91% to $1.0 million in 2024, then soared by 7410.3% to $75.1 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Cash from Financing Activities are $75.1 million (Q4 2025), $480000.0 (Q3 2025), and $507000.0 (Q2 2025).